Hercules Capital Stock Forecast for 2023 - 2025 - 2030
Updated on 04/16/2024
Hercules Capital Stock Forecast and Price Target
The average price target for Hercules Capital's stock lately set by several renowned analysts is $18.00, which would result in a potential upside of approximately 0.06% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $21.00 and a low estimate of $16.00. Even if not interested in HTGC stock, you may want to be aware of its competitors.
0.06% Upside
Hercules Capital Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Hercules Capital's Price has decreased from $13.61 to $0.00 – a 100.00% drop. The next year looks promising for Hercules Capital, with analysts predicting Fair Value of $19.58 – an increase of 100.00%. Over the next eight years, experts anticipate that Hercules Capital's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.00 | Buy/Sell | CHF105.00 | 24.07% |
SAN Stock Forecast | Sanofi | Outperform |
16
|
86.79€ | Buy/Sell | 102.80€ | 24.44% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.26 | Buy/Sell | $58.15 | 13.97% |
MRK Stock Forecast | Merck KGaA | Outperform |
18
|
151.10€ | Buy/Sell | 190.06€ | 21.11% |
BIIB Stock Forecast | Biogen | Outperform |
10
|
$195.15 | Buy/Sell | $299.62 | 49.63% |
Hercules Capital Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Hercules Capital's Revenue has grown, increasing from $287.26M to $460.67M – a growth of 60.37%. The next year looks promising for Hercules Capital, with analysts predicting Revenue of $488.10M – an increase of 5.95%. Over the next eight years, experts anticipate that Hercules Capital's Revenue will grow at a rate of 7.63%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BAYN Stock Forecast | Bayer | Hold |
5
|
26.08€ | Buy/Sell | 45.15€ | 26.53% |
GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr2.06k | Buy/Sell | kr2.71k | 24.64% |
TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.09 | Buy/Sell | $11.59 | 22.23% |
Hercules Capital Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Hercules Capital's Dividend per Share has grown by 24.22%, from $1.28 to $1.59. For the next year, analysts are expecting Dividend per Share to reach $1.63 – an increase of 2.52%. Over the next eight years, experts predict that Dividend per Share will grow by 2.43%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ARCC Stock Forecast | Ares Capital | Outperform |
14
|
$20.24 | Buy/Sell | $21.50 | 8.70% |
FSK Stock Forecast | FS KKR Capital | Hold |
13
|
$18.85 | Buy/Sell | $21.55 | 6.10% |
ALKS Stock Forecast | Alkermes | Outperform |
10
|
$23.77 | Buy/Sell | $33.27 | 47.24% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MAIN Stock Forecast | Main Street Capital | Hold |
12
|
$46.77 | Buy/Sell | $44.17 | -3.78% |
GBDC Stock Forecast | Golub Capital BDC | Outperform |
14
|
$16.57 | Buy/Sell | $15.90 | 2.60% |
PSEC Stock Forecast | Prospect Capital | Underperform |
12
|
$5.38 | Buy/Sell | $5.50 | -2.42% |
Hercules Capital EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Hercules Capital's EBITDA has grown by 70.07%, rising from $224.43M to $381.69M. In the following year, the 0 analysts surveyed believe that Hercules Capital's EBITDA will decrease by 14.68%, reaching $325.67M. According to professionals, by 2030, Hercules Capital's EBITDA will have decreased by 20.78%, falling down to $302.38M.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
TSLX Stock Forecast | Sixth Street Specialty Lending | Outperform |
14
|
$20.55 | Buy/Sell | $21.91 | 9.49% |
GSBD Stock Forecast | Goldman Sachs BDC | Hold |
12
|
$14.96 | Buy/Sell | $14.50 | 0.27% |
OCSL Stock Forecast | Oaktree Specialty Lending Corp | Outperform |
14
|
$19.29 | Buy/Sell | $7.79 | 4.98% |
Hercules Capital EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Hercules Capital's EBIT has grown by 70.30%, rising from $224.01M to $381.50M. The next year, 0 experts forecast that Hercules Capital's EBIT will decrease by 14.71%, reaching $325.37M. In 2030, professionals predict that Hercules Capital's EBIT will decrease by 20.81%, reaching $302.12M.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NMFC Stock Forecast | New Mountain Finance | Outperform |
14
|
$12.39 | Buy/Sell | $13.14 | 4.92% |
CSWC Stock Forecast | Capital Southwest | Outperform |
15
|
$24.42 | Buy/Sell | $22.81 | 6.47% |
BBDC Stock Forecast | Barings BDC | Outperform |
16
|
$9.18 | Buy/Sell | $9.86 | 11.66% |
Hercules Capital EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Hercules Capital's EPS has decreased from $1.39 to $0.00 – a 100.00% drop. The next year looks promising for Hercules Capital, with analysts predicting EPS of $2.00 – an increase of 100.00%. Over the next eight years, experts anticipate that Hercules Capital's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MFIC Stock Forecast | MidCap Financial Investment | Outperform |
13
|
$14.77 | Buy/Sell | $13.86 | 1.56% |
SLRC Stock Forecast | SLR Investment | Hold |
12
|
$14.80 | Buy/Sell | $15.50 | 8.11% |
CGBD Stock Forecast | Carlyle Secured Lending | Hold |
14
|
$16.39 | Buy/Sell | $15.42 | -2.38% |